The Journal of Headache and Pain

Official Journal of the "European Headache Federation" and of "Lifting The Burden - The Global Campaign against Headache"

The Journal of Headache and Pain Cover Image

Volume 15 Supplement 1

Abstracts from the 4th European Headache and Migraine Trust International Congress: EHMTIC 2014

Open Access

EHMTI-0126. Superiority of algopirin® versus excedrin® in treating migraine. Individual pain values and pain curves comparisons

  • C Mircioiu1,
  • V Voicu2 and
  • I Mircioiu3
The Journal of Headache and Pain201415(Suppl 1):G25

Published: 18 September 2014


MigraineCaffeineVisual Analog ScalePain ReliefAcetaminophen


A synergic association between acetylsalycilic acid, acetaminophen, caffeine in doses 3-4 times lower than similar combinations and chlorpheniramine was patented and marketed as analgesic drug. A previous study proved the non-inferiority of a unique dose of treatment using Algopirin®, versus Excedrin® similar association.

Aim of the research was to prove superiority of two tablets Algopirin® versus one tablet Excedrin® in treating migraine.


Patients treated two independent migraine episodes of at least moderate intensity with Algopirin® in first period and with Excedrin® (Novartis) in second period. All patients recorded the pain severity on a Visual Analog Scale before and 30, 60, 120, 180 and 240 min after drug intake. Comparison of the mean pain intensities was performed using paired t test and Wilcoxon pair signed rank test. Interpretation of pain curves as “survival pain curves” allowed application of statistical methods usual in cancer research. Comparison of areas under curves was performed similar with comparison of plasma levels of drugs in pharmacokinetics.


Effect of Algopirin® was greater than that of Excedrin®. Mean time to 50 % (T50) pain relief was 30 min for Algopirin® and 45 min for Excedrin. Time to pain relief to 20 % (T20) was 85 min for Algopirin® and 180 min for Excedrin®. Difference between effects measured by areas under curves was 11%. All differences were statistically significant (p<0.01).


In spite of the fact that Algopirin® contains lower doses of active components, its effect on pain curves in migraine is superior to Excedrin®.

No conflict of interest.

Authors’ Affiliations

Biostatistics, UMF Carol Davila, Bucharest, Romania
Clinical Pharmmacology and Toxicology, UMF Carol Davila, Bucharest, Romania
Biopharmacy, Ovidius University, Constanta, Romania


© Mircioiu et al; licensee Springer. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.